Cadila Healthcare's Baddi unit receives 3 observations under Form 483
Observations, given by US FDA, are related to pre-approval inspection for a specific product filed
 "Cadila Healthcare’s Baddi unit receives 3 observations under Form 483")
premium
Following an inspection by the US Food & Drug Administration (FDA) from February 20, 2017 to March 1, 201, Cadila Healthcare’s formulations manufacturing facility at Baddi (Himachal Pradesh) has received three observations given under Form 483 from the US dug regulator. All these three observations are related to pre-approval inspection (PAI) for a specific product filed.